Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449850 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL19999152 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL3896363 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL2558543 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL12595176 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL15307981 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL26815263 | 0.95 | ALDH1A1 (0.44) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL14706736 | 0.94 | ALDH1A1 (0.43) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL1145153 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA9CA1GAA | |
| SCHEMBL478342 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA9CA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| US-9617222-B1 | Alkynyl indazole derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | BIOZONE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | ALDH1A1 1503/4885CA12 4354/4885CA9 4490/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA9 3970/4885 |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | ALDH1A1 1503/4885CA12 4354/4885CA9 4490/4885 |
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | LIPA, CETP, DGAT2 | ALDH1A1 2451/4885CA12 2560/4885CA9 2545/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA9 3970/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | ALDH1A1 1759/4885CA12 4092/4885CA9 4181/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA9 3970/4885 |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 551/4885CA12 4108/4885CA9 1847/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | ALDH1A1 1759/4885CA12 4092/4885CA9 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.